Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th
SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be presenting at the 2022 Ladenburg Thalmann Healthcare Conference being held on September 29, 2022 at the Sofitel Hotel in New York City.
Related news for (ARTL)
- Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset
- 24/7 Market News Snapshot 04 August, 2025 – Artelo Biosciences, Inc. Common Stock (NASDAQ:ARTL)
- Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
- Today’s Top Performers: MoBot’s Market Review 07/07/25 05:00 PM
- Breaking News: MoBot’s Latest Update as of 07/07/25 04:00 PM